Cas12a CRISPR mRNA for T-Rich Genome Editing

Why Choose Cas12a Instead of Cas9?
Compared to Cas9, Cas12a offers unique advantages in genome editing:
• Recognizes T-rich PAM sequences (TTTV), expanding targeting flexibility
• Generates staggered DNA cleavage instead of blunt ends
• Requires only a single crRNA without tracrRNA
• Enables multiplex gene editing with simplified design

These features make Cas12a an attractive tool for applications where Cas9 is limited.

▶︎Download Flyer (PDF)
 

When to use Cas12a instead of Cas9 in CRISPR gene editing?

Cas12a (Cpf1) is widely used in gene editing applications that require T-rich PAM recognition (TTTV), which cannot be targeted by Cas9. It also generates staggered DNA breaks, offering advantages in specific genome engineering strategies.
This page provides an overview of Cas12a CRISPR mRNA performance, along with experimental data and downloadable flyer for reference.


Cas12a (Cpf1) is an alternative CRISPR nuclease that expands genome editing possibilities beyond Cas9. Unlike Cas9, Cas12a recognizes T-rich PAM sequences (5'-TTTV-3') and introduces staggered DNA double-strand breaks, making it highly suitable for specific genomic targets that are not accessible with Cas9 systems.
CROYEZ Cas12a CRISPR mRNA is designed for efficient transient expression, enabling rapid genome editing without genomic integration. This makes it an ideal solution for researchers working on gene editing, cell therapy development, and advanced CRISPR applications.


Applications of Cas12a CRISPR mRNA
CROYEZ Cas12a mRNA is suitable for a wide range of gene editing applications:
• Genome editing in T-rich PAM regions  
• Multiplex CRISPR editing  
• Cell therapy and immunotherapy research  
• Functional genomics studies  
• Alternative CRISPR system development  

Its mRNA format allows rapid expression and controlled editing activity, making it ideal for transient delivery systems such as LNP.